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Abstract
The use of corticosteroids for the treatment of community-acquired
pneumonia has been reported for almost 50 years. A recent sys-
tematic analysis of the relevant literature suggested that cortico-
steroids reduce the critical illness associated with community-
acquired pneumonia. There is little doubt that a prolonged adminis-
tration of a moderate dose of corticosteroids may alleviate the
systemic inflammatory response and subsequent organ dys-
function in severe infection. Whether these favorable effects on
morbidity may translate into better survival and quality of life needs
to be addressed in additional adequately powered randomized
controlled trials.
In the previous issue of Critical Care, Salluh and colleagues
[1] suggested evidence-based recommendations for cortico-
steroid therapy in community-acquired pneumonia. Cortico-
steroids have been used as an adjunct therapy for severe
infection for roughly half a century. Contrasting with the
clinical practice, researchers are continuing to argue the pros
and cons of this therapeutic approach [2].
What is the basis for corticosteroids in
community-acquired pneumonia?
In the era of powerful antibiotics, the likelihood of uncon-
trolled infection and bacterial proliferation has become less
significant. Thus, uncontrolled and overwhelming systemic
inflammation is likely the main pathogenetic culprit for
progression to organ failure and death in infected patients,
such as those with community-acquired pneumonia [3].
Several decades of research on host response to stress have
characterized the critical role of an intact hypothalamic-
pituitary-adrenal response (that is, appropriate tissue levels of
corticosteroids) to prevent dissemination of pro-inflammatory
storm from one organ to another following local infection [4].
Unsurprisingly, in community-acquired pneumonia, a blunted
hypothalamic-pituitary-adrenal axis was clearly associated
with the worsening of patient condition [5-7]. More broadly,
the concept of critical illness-related corticosteroid insuffici-
ency, defined as inadequate intracellular glucocorticoid anti-
inflammatory activity for the severity of the patient’s illness,
has become readily accepted by endocrinologists and
intensivists [8]. Ample evidence has shown that prolonged
treatment with a moderate dose of corticosteroids can
improve intracellular downregulation of inflammatory cytokine
transcription and accelerate the resolution of critical illness
[8]. New advances in our understanding of the molecular
mechanisms of corticosteroid action and its implications for
sepsis were recently reviewed [8]. In addition, the recent
literature has provided strong experimental support for the
use of prolonged corticosteroid treatment in pneumonia [9].
What is the clinical benefit from corticosteroids
in community-acquired pneumonia?
In the previous issue of Critical Care, Salluh and colleagues
[1] reviewed four studies investigating corticosteroid treat-
ment in community-acquired pneumonia, including three
randomized controlled trials and one retrospective study.
Increased survival was reported in two studies investigating
treatment duration equal to or greater than 7 days, and lack of
survival benefit was reported with short duration of treatment.
The authors found evidence for a rather favorable benefit-risk
profile with improvement in physiological and clinical
outcomes and no evidence for increased harm. The use of
corticosteroid treatment in sepsis dates back to the early
1950s [10], and in 1956, favorable effects of hydrocortisone
(80 mg/day orally) were reported in patients with pneumo-
coccal pneumonia [11]. In addition to the above studies,
subgroup analyses for patients with community-acquired
pneumonia were recently provided from two randomized trials
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investigating prolonged corticosteroid treatment in patients
with septic shock and acute respiratory distress syndrome
(ARDS) [12]. In septic shock, 101 of 300 patients had
community-acquired pneumonia; corticosteroid-treated patients
(n = 47) had improved survival with a hazard ratio of 0.55
(95% confidence interval 0.32 to 0.95). In the ARDS trial, 25
of 91 patients had severe community-acquired pneumonia;
treated patients had a non-statistically significant increase in
the rate of extubation by day 7 (61% versus 14%; P = 0.07)
and reductions in the median duration of mechanical
ventilation (5 versus 10 days; P = 0.13), in C-reactive protein
levels in plasma (2.5 ± 1.8 versus 12.1 ± 8.1 mg/L;
P = 0.06), and in hospital mortality (16.5% versus 42.5%;
P = 0.3) [11]. It is also important to remember that prolonged
corticosteroid treatment has already been proven effective in
decreasing mortality in two forms of life-threatening pneu-
monia:  Pneumocystis jiroveci pneumonia [13] and severe
acute respiratory syndrome [14].
What is the potential harm from corticosteroids
in community-acquired pneumonia?
In theory, corticosteroids may favor the onset of gastro-
duodenal bleeding, superinfection, metabolic disorders, and
muscle weakness. A recent systematic review on the use of
corticosteroids for severe sepsis and septic shock, however,
failed to show any evidence for an increased risk of bleeding,
superinfection, or neuromuscular weakness, whereas hyper-
natremia and hyperglycaemia occurred more frequently in
treated patients (D. Annane, personal communication). It is
important for physicians to implement preventive measures
and to perform daily screening for possible complications. A
specific surveillance of potential sites of superinfection and
control of blood glucose and serum sodium levels should be
systematically performed.
Which action should be taken now?
For clinical practice, the favorable benefit-risk profile of a
moderate dose of corticosteroids reasonably supports its use
in the most severe cases of community-acquired pneumonia
with high predicted mortality (that is, patients with shock,
respiratory failure, or those with progression of organ
dysfunction despite receiving appropriate antibiotics). Most
conclusive answers and recommendations, however, can be
obtained only with additional research. Pneumonia is the
leading cause of sepsis-associated death in the world, with
little reduction in mortality achieved over the last 50 years
[15]. It is the responsibility of our scientific community and
government agencies to promptly set up a large international
randomized controlled trial to definitely characterize the
benefits and the potential harm of corticosteroids when given
to patients with community-acquired pneumonia. A public
consensus among experts on the design of future randomized
trials will facilitate the progress of this important research.
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